Structure of complement receptor (CR) 2 and CR2-C3d complexes. 2002

J Hannan, and K Young, and G Szakonyi, and M J Overduin, and S J Perkins, and X Chen, and V M Holers
Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA.

Using X-ray crystallography, we have determined the structure of the first two short consensus repeats (SCRs) of human complement receptor (CR) 2 in complex with C3d. These studies revealed: (i) a primary site of interaction for C3d within SCR2 of CR2, (ii) a hydrophobic patch holding SCR1 to SCR2 in a rigid V-shape, (iii) a dimer formed by interactions between SCR1 of each molecule, (iv) several non-linear sequences on C3d that interact with CR2 and (v) mutations of C3d amino acids within the co-crystal interface that resulted in decreased binding. In addition, a polymorphism that results in decreased C3d binding and introduces a new glycosylation site predicted to disrupt the dimer interface was found in the New Zealand White autoimmune mouse strain. Although the co-crystal complex results are in agreement with a subset of prior studies, our additional findings, which demonstrate an extended SCR1-SCR2 structure in solution and differences in the kinetics of ligand-receptor interactions with longer forms of CR2, have suggested a more complex receptor-ligand interaction. To characterize this interaction further, several approaches directed at the determination of solution phase interactions as well as the analysis of the three-dimensional structure of CR2 alone and key CR2 mutants will be necessary.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009502 Neutrons Electrically neutral elementary particles found in all atomic nuclei except light hydrogen; the mass is equal to that of the proton and electron combined and they are unstable when isolated from the nucleus, undergoing beta decay. Slow, thermal, epithermal, and fast neutrons refer to the energy levels with which the neutrons are ejected from heavier nuclei during their decay. Neutron
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012542 Scattering, Radiation The diversion of RADIATION (thermal, electromagnetic, or nuclear) from its original path as a result of interactions or collisions with atoms, molecules, or larger particles in the atmosphere or other media. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Radiation Scattering,Radiation Scatterings,Scatterings, Radiation
D015933 Complement C3d A 302-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c, and C3dg (955-1303) in the presence COMPLEMENT FACTOR H. Serum proteases further degrade C3dg into C3d (1002-1303) and C3g (955-1001). C3d Complement,Complement 3d,Complement C3d Fragment,Complement Component 3d,C3d Fragment, Complement,C3d, Complement,Complement, C3d,Component 3d, Complement,Fragment, Complement C3d
D017455 Receptors, IgE Specific molecular sites on the surface of B- and T-lymphocytes which combine with IgEs. Two subclasses exist: low affinity receptors (Fc epsilon RII) and high affinity receptors (Fc epsilon RI). Antigens, CD23,CD23 Antigens,Fc Receptors, epsilon,Fc epsilon Receptor,Fc epsilon Receptors,IgE Receptor,IgE Receptors,Receptors, Fc epsilon,epsilon Fc Receptor,epsilon Fc Receptors,CD 23 Antigens,CD23 Antigen,Fc epsilon RI,Fc epsilon RII,Immunoglobulin E Receptor,Antigen, CD23,Antigens, CD 23,Fc Receptor, epsilon,Receptor, Fc epsilon,Receptor, IgE,Receptor, Immunoglobulin E,Receptor, epsilon Fc,Receptors, epsilon Fc,epsilon RI, Fc,epsilon RII, Fc,epsilon Receptor, Fc,epsilon Receptors, Fc

Related Publications

J Hannan, and K Young, and G Szakonyi, and M J Overduin, and S J Perkins, and X Chen, and V M Holers
February 2010, Journal of immunology (Baltimore, Md. : 1950),
J Hannan, and K Young, and G Szakonyi, and M J Overduin, and S J Perkins, and X Chen, and V M Holers
July 1985, The Journal of investigative dermatology,
J Hannan, and K Young, and G Szakonyi, and M J Overduin, and S J Perkins, and X Chen, and V M Holers
January 2016, Current protein & peptide science,
J Hannan, and K Young, and G Szakonyi, and M J Overduin, and S J Perkins, and X Chen, and V M Holers
June 2001, Science (New York, N.Y.),
J Hannan, and K Young, and G Szakonyi, and M J Overduin, and S J Perkins, and X Chen, and V M Holers
June 1990, The Journal of investigative dermatology,
J Hannan, and K Young, and G Szakonyi, and M J Overduin, and S J Perkins, and X Chen, and V M Holers
November 2001, Journal of immunology (Baltimore, Md. : 1950),
J Hannan, and K Young, and G Szakonyi, and M J Overduin, and S J Perkins, and X Chen, and V M Holers
January 1988, Annual review of immunology,
J Hannan, and K Young, and G Szakonyi, and M J Overduin, and S J Perkins, and X Chen, and V M Holers
June 1985, Proceedings of the National Academy of Sciences of the United States of America,
J Hannan, and K Young, and G Szakonyi, and M J Overduin, and S J Perkins, and X Chen, and V M Holers
December 2008, Journal of molecular biology,
J Hannan, and K Young, and G Szakonyi, and M J Overduin, and S J Perkins, and X Chen, and V M Holers
November 1986, Molecular immunology,
Copied contents to your clipboard!